Alpha 2.0
Login Register
» Authors » Celine Chevaleyre

Celine Chevaleyre

Explore the profile of Celine Chevaleyre including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 30
Followers 0
Related Specialties
Pharmacology
Biochemistry
Oncology
Top 10 Co-Authors
Dimitri Kereselidze
Charles Truillet
Steven Dubois
Herve Nozach
Benoit Jego
Bernard Maillere
Alizee Bouleau
Nicolas Tournier
Simon Specklin
Vincent Lebon
Published In
J Nucl Med
Fundam Clin Pharmacol
Int J Mol Sci
Theranostics
Mol Pharm
Affiliations
Soon will be listed here.
Recent Articles
1.
PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy
Chevaleyre C, Zimmermann L, Specklin S, Kereselidze D, Bouleau A, Dubois S, et al.
J Nucl Med . 2025 Feb; PMID: 39978814
The development of resistance significantly hampers the efficacy of immunotherapies in cancer treatment. The combination of JQ1, a BRD4 protein inhibitor, and anti-programmed death ligand 1 (PD-L1) immunotherapies has a...
2.
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
Meyblum L, Chevaleyre C, Susini S, Jego B, Deschamps F, Kereselidze D, et al.
J Immunother Cancer . 2023 Nov; 11(11). PMID: 37949616
Background: Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral delivery of immunotherapies...
3.
Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction
Chevaleyre C, Novell A, Tournier N, Dauba A, Dubois S, Kereselidze D, et al.
Theranostics . 2023 Nov; 13(15):5584-5596. PMID: 37908736
The passage of antibodies through the blood-brain barrier (BBB) and the blood-tumoral barrier (BTB) is determinant not only to increase the immune checkpoint inhibitors efficacy but also to monitor prognostic...
4.
TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model
Chevaleyre C, Kereselidze D, Caille F, Tournier N, Olaciregui N, Winkeler A, et al.
Int J Mol Sci . 2022 Oct; 23(20). PMID: 36293329
Diffuse intrinsic pontine gliomas (DIPG), the first cause of cerebral pediatric cancer death, will greatly benefit from specific and non-invasive biomarkers for patient follow-up and monitoring of drug efficacy. Since...
5.
Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand
Tran V, Bouleau A, Nozach H, Richard M, Chevaleyre C, Dubois S, et al.
Mol Pharm . 2022 Aug; 19(10):3673-3680. PMID: 35998011
Molecular imaging with PET offers an alternative method to quantify programmed-death-ligand 1 (PD-L1) to accurately select patients for immunotherapies. More and more clinical and preclinical trials involve radiolabeling of antibody...
6.
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Zr-Labeled Anti-PD-L1 Antibody Formats
Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, Wang C, et al.
J Nucl Med . 2021 Dec; 63(8):1259-1265. PMID: 34933891
PET imaging of programmed cell death ligand 1 (PD-L1) may help to noninvasively predict and monitor responses to anti-programmed cell death 1/anti-PD-L1 immunotherapies. In this study, we compared the imaging...
7.
Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients
Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, et al.
Fundam Clin Pharmacol . 2017 Nov; 32(2):239-248. PMID: 29091319
Baclofen has been proposed for few years to help treating alcohol dependence at higher doses than those used in neurology. Baclofen pharmacokinetics has been previously well described at low oral...